Intra-individual stability over time of standardized anti-Müllerian hormone in FMR1 premutation carriers

• Published in: Human reproduction (Oxford) Vol. 26; no. 8; pp. 2185 - 2191
• Main Authors: Spath, M.A., Feuth, T.B., Allen, E.G., Smits, A.P.T., Yntema, H.G., van Kessel, A. Geurts, Braat, D.D.M., Sherman, S.L., Thomas, C.M.G.
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01-08-2011
• Subjects: Adolescent; Adult; Aged; Aging; Anti-Mullerian Hormone - blood; Female; Fragile X Mental Retardation Protein - genetics; Heterozygote; Humans; Middle Aged; Original; Primary Ovarian Insufficiency - etiology; Primary Ovarian Insufficiency - genetics; Repetitive Sequences, Nucleic Acid; ovarian reserve; anti-Müllerian hormone (AMH); gene; premutation carriers; fragile X-associated primary ovarian insufficiency (FXPOI)
• ISSN: 0268-1161; 1460-2350
• DOI: 10.1093/humrep/der146

BACKGROUND
Carriers of a premutation (CGG repeat length 55–200) in the fragile X mental retardation (FMR1) gene are at risk for primary ovarian insufficiency (FXPOI). The anti-Müllerian hormone (AMH) level acts as a useful marker of ovarian follicle reserve and, thus, may serve to predict when this ovarian reserve becomes too low to sustain ovarian function. We investigated the intra-individual variation of AMH levels over time for premutation carriers compared with non-carriers.
METHODS
We determined AMH levels in blood samples from 240 women ascertained through fragile X families, of which 127 were premutation carriers and 113 were non-carriers. Linear mixed models were used to assess the effect of age and premutation status on AMH levels and to determine a modeled AMH value. The stability over time of the deviation of observed AMH levels from modeled levels, referred to as standardized AMH values, was assessed through correlation coefficients of 41 longitudinal samples.
RESULTS
At all ages, premutation carriers exhibited lower AMH levels. For all women, AMH was found to decrease by 10% per year. The added effect of having a premutation decreased AMH levels by 54%. The deviation of an individual's AMH level from the modeled value showed a reasonable intra-individual correlation. The Pearson correlation coefficient of two samples taken at different ages was 0.36 (P = 0.05) for non-carriers and 0.69 (P = 0.01) for carriers.
CONCLUSIONS
We developed a unique standardized AMH value, taking FMR1 premutation status and the subject's age into account, which appears to be stable over time and may serve as a predictor for FXPOI after further longitudinal assessment.